2017
Risk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis.
Stuckelman ZD, Mulqueen JM, Ferracioli-Oda E, Cohen SC, Coughlin CG, Leckman JF, Bloch MH. Risk of Irritability With Psychostimulant Treatment in Children With ADHD: A Meta-Analysis. The Journal Of Clinical Psychiatry 2017, 78: e648-e655. PMID: 28682529, DOI: 10.4088/jcp.15r10601.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderRisk of irritabilitySide effectsPsychostimulant medicationPsychostimulant treatmentAmphetamine derivativesPlacebo-controlled trialCommon side effectsStratified subgroup analysisEffects of amphetamineTreatment of childrenDuration of usePsychostimulant classesEligible trialsMedical comorbiditiesHead trialsSubgroup analysisRisk ratioRelative riskSTUDY SELECTIONEffective treatmentDATA SOURCESPubMed searchTrial designStimulant type
2016
N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial
Bloch MH, Panza KE, Yaffa A, Alvarenga PG, Jakubovski E, Mulqueen JM, Landeros-Weisenberger A, Leckman JF. N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial. Journal Of Child And Adolescent Psychopharmacology 2016, 26: 327-334. PMID: 27027204, PMCID: PMC6445198, DOI: 10.1089/cap.2015.0109.Peer-Reviewed Original ResearchConceptsBenefit of NACEfficacy of NACYale Global Tic Severity ScaleAttention-deficit/hyperactivity disorderObsessive-compulsive disorderTourette syndromeN-acetylcysteineObsessive-compulsive spectrum disordersSide effectsRecent placebo-controlled trialPediatric Tourette syndromePlacebo-controlled trialCurrent pharmacological treatmentsTreatment of ticsTotal tic scoreSeverity of ticsSubstantial side effectsTic Severity ScaleYears of ageMinimal side effectsPediatric TSPrimary outcomeSecondary outcomesGlutamatergic systemPharmacological treatment
2003
Tourette’s syndrome in children
Swain JE, Leckman JF. Tourette’s syndrome in children. Current Treatment Options In Neurology 2003, 5: 299-308. PMID: 12791197, DOI: 10.1007/s11940-003-0036-6.Peer-Reviewed Original ResearchTourette syndromeSide effectsComorbid conditionsPharmacologic agentsCourse of ticsLow-dose neurolepticsRealistic treatment expectationsAvailable pharmacologic agentsAttention deficit hyperactivity disorderBenefits of interventionsCommitted cliniciansDeficit hyperactivity disorderObsessive-compulsive disorderTreatment optionsSuccessful treatmentClinical trialsSomatic treatmentsTreatment responseSpecific symptomsEffective treatmentCommon treatmentTreatment expectationsTic severityTic controlNeurophysiologic basis
2001
Tic disorders: when habit forming neural systems form habits of their own?
Leckman JF, Yeh CB, Cohen DJ. Tic disorders: when habit forming neural systems form habits of their own? Journal Of The Chinese Medical Association 2001, 64: 669-92. PMID: 11922487.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderTourette syndromeAttention-deficit/hyperactivity disorderBasal gangliaIntolerable side effectsSubgroup of patientsLong-term outcomesAlpha-adrenergic agentsMajor affective disordersSpecific brain circuitsNew therapeutic directionDeficit/hyperactivity disorderAutoimmune mechanismsEarly brain developmentComorbid conditionsAtypical neurolepticsClinical neuroscience researchClinical trialsPrevalent disorderChildhood onsetClinical careMarked impairmentSide effectsPharmacological techniquesAffective disorders
1986
Assessment or central dopaminergic function using plasma-free homovanillic acid after debrisoquin administration
Riddle MA, Leckman JF, Cohen DJ, Anderson M, Ort SI, Caruso KA, Shaywitz BA. Assessment or central dopaminergic function using plasma-free homovanillic acid after debrisoquin administration. Journal Of Neural Transmission 1986, 67: 31-43. PMID: 3465864, DOI: 10.1007/bf01243357.Peer-Reviewed Original ResearchConceptsCentral dopaminergic functionDopaminergic functionHomovanillic acidDopamine metabolite homovanillic acidCentral DA activityChronic oral administrationPlasma-free homovanillic acidSingle oral doseBlood-brain barrierMetabolite homovanillic acidBehavioral side effectsOral dosePeripheral metabolismDA activityOral administrationSide effectsDebrisoquinAdministration methodsMarked reductionHVAAdministrationPeripheral formationAdultsValid techniqueChildren
1985
Short- and long-term treatment of Tourette's syndrome with clonidine: a clinical perspective.
Leckman J, Detlor J, Harcherik D, Ort S, Shaywitz B, Cohen D. Short- and long-term treatment of Tourette's syndrome with clonidine: a clinical perspective. Neurology 1985, 35: 343-51. PMID: 3883235, DOI: 10.1212/wnl.35.3.343.Peer-Reviewed Original ResearchConceptsTourette syndromeGilles de la Tourette's syndromePlacebo-controlled trialDouble-blind studyLong-term treatmentSerious side effectsLa Tourette's syndromeUnequivocal respondersPhonic ticsClonidineSide effectsSyndromeDrug efficacyEquivocal responseClinical perspectivePatientsEfficacyBehavior problemsSignificant improvementRespondersTrialsWeeks
1982
Clonidine in the treatment of Tourette syndrome: a review of data.
Leckman JF, Cohen DJ, Detlor J, Young JG, Harcherik D, Shaywitz BA. Clonidine in the treatment of Tourette syndrome: a review of data. Advances In Neurology 1982, 35: 391-401. PMID: 6756089.Peer-Reviewed Original ResearchConceptsTS patientsLong-term symptomatic improvementPathophysiology of TSDouble-blind trialEfficacy of clonidineMinority of patientsGrowth hormone releasePrimary pathogenic importanceMinimal side effectsSymptomatic improvementBlood pressureProfile of responseNoradrenergic mechanismsMHPG levelsTherapeutic responseHormone releaseClonidinePathogenic importanceAcute dosesSide effectsTourette syndromeBehavioral symptomsPharmacologic investigationsNeurochemical systemsPatients